<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27416" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Polymyalgia Rheumatica</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Acharya</surname>
            <given-names>Saurav</given-names>
          </name>
          <aff>University of Tennessee HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Musa</surname>
            <given-names>Rina</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saurav Acharya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rina Musa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27416.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in White adults older than 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the common findings. PMR patients can develop or have concomitant giant cell arteritis (GCA). Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR.&#x000a0;</p>
        <p>Clinicians participating in this activity can expect to gain a comprehensive understanding of PMR, including its clinical manifestations, association with GCA, and challenges in diagnosis and long-term management. The activity emphasizes the role of the interprofessional team in effectively addressing the complexities of PMR, providing valuable insights into improved patient care and outcomes. Topics covered include the cause, pathophysiology, and presentation of PMR, empowering clinicians with the knowledge and skills to navigate the intricacies of this inflammatory disorder in older adults.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of polymyalgia rheumatica.</p></list-item><list-item><p>Differentiate polymyalgia rheumatica from other rheumatic conditions through a comprehensive understanding of its clinical manifestations, laboratory findings, and imaging studies.</p></list-item><list-item><p>Implement evidence-based treatment strategies for managing patients with polymyalgia rheumatica.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team&#x000a0;to optimize comprehensive care for patients with polymyalgia rheumatica.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27416&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27416">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27416.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area that significantly impacts quality of life. This disorder is more common in&#x000a0;white adults over 50 years of age. It is an inflammatory&#x000a0;condition associated with an elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), being the typical findings. Patients with PMR can develop or have concomitant giant cell arteritis (GCA), &#x000a0;also known as Horton disease. Some authors consider GCA an extreme entity of the same spectrum of disorders as PMR.</p>
        <p>Understanding the intricacies of PMR is essential for clinicians, as it requires a nuanced approach to management, including careful consideration of the potential long-term complications and the crucial interplay with GCA. This review aims to highlight the key aspects of PMR,&#x000a0;including the etiology, clinical features, and optimal management strategies.&#x000a0;</p>
      </sec>
      <sec id="article-27416.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;PMR is not well-understood.</p>
        <p>Familial aggregation of PMR&#x000a0;has suggested a genetic predisposition.<xref ref-type="bibr" rid="article-27416.r1">[1]</xref> HLA class II alleles are found to be&#x000a0;associated with PMR, and among these, the HLA-DRB1*04 allele correlates most frequently, seen in up to 67% of cases.<xref ref-type="bibr" rid="article-27416.r2">[2]</xref> Genetic polymorphisms for ICAM-1, RANTES, and IL-1 receptors also appear to play a role in the pathogenesis of PMR in some populations.<xref ref-type="bibr" rid="article-27416.r3">[3]</xref></p>
        <p>There were reports of increased incidence of PMR along with GCA during epidemics of mycoplasma pneumonia and parvovirus B19 in Denmark, suggesting a possible role of infection in etiopathogenesis.<xref ref-type="bibr" rid="article-27416.r4">[4]</xref>&#x000a0;The Epstein-Barr virus (EBV) has also&#x000a0;been proposed as a possible&#x000a0;trigger for PMR.<xref ref-type="bibr" rid="article-27416.r5">[5]</xref>&#x000a0;However, several other studies have not supported an infectious etiology hypothesis.<xref ref-type="bibr" rid="article-27416.r6">[6]</xref><xref ref-type="bibr" rid="article-27416.r7">[7]</xref></p>
        <p>There are also reports of an association between PMR and diverticulitis, which could suggest a role of a change in microbiota and chronic&#x000a0;bowel inflammation in&#x000a0;the immunopathogenesis of the disease.<xref ref-type="bibr" rid="article-27416.r8">[8]</xref></p>
        <p>A case series of&#x000a0;previously healthy subjects developing GCA/PMR after&#x000a0;influenza vaccination also exists.<xref ref-type="bibr" rid="article-27416.r9">[9]</xref> Vaccine adjuvants can trigger autoimmunity-causing autoimmune/inflammatory syndrome induced by adjuvants (ASIA), which can have clinical features similar to PMR.</p>
      </sec>
      <sec id="article-27416.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The annual incidence of&#x000a0;PMR&#x000a0;in individuals aged 50 years or older was found to be between&#x000a0;58 to 96 per 100,000 population, specifically predominantly White populations.&#x000a0;Incidence rates increase with age until 80 years.<xref ref-type="bibr" rid="article-27416.r10">[10]</xref><xref ref-type="bibr" rid="article-27416.r11">[11]</xref>&#x000a0;</p>
        <p>PMR has been&#x000a0;reported as the second most common inflammatory autoimmune rheumatic disease after rheumatoid arthritis in some predominantly White populations. It is at least twice as common as GCA and is found in approximately 50% of patients with GCA.<xref ref-type="bibr" rid="article-27416.r12">[12]</xref> PMR is much less common in Black, Asian, and Hispanic populations.</p>
      </sec>
      <sec id="article-27416.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PMR is an immune-mediated disorder, and elevated inflammatory markers are common. IL-6 is key in mediating inflammation and is elevated in both PMR and GCA.<xref ref-type="bibr" rid="article-27416.r13">[13]</xref> Interferon (IFN) may be present in temporal artery biopsies in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis.<xref ref-type="bibr" rid="article-27416.r14">[14]</xref>&#x000a0;</p>
        <p>An elevated IgG4 level was&#x000a0;found in patients with PMR but less frequently in patients with GCA.<xref ref-type="bibr" rid="article-27416.r15">[15]</xref> The same study discovered an increased number of patients with PMR features without&#x000a0;elevation&#x000a0;of&#x000a0;IgG4 disease&#x000a0;to have simultaneous GCA.&#x000a0;</p>
        <p>Patients with PMR have a decreased number of circulating B cells compared to healthy adults. The circulating B cell number inversely correlates with ESR and CRP. This altered distribution of B cells possibly contributes to the IL-6 response in PMR.<xref ref-type="bibr" rid="article-27416.r16">[16]</xref>&#x000a0;</p>
        <p>Autoantibodies with a significant role in pathogenesis are not a feature of PMR. Like GCA, patients with PMR also have decreased&#x000a0;regulatory T (Treg) cells and T helper (Th)1 cells and increased&#x000a0;Th17 cells.<xref ref-type="bibr" rid="article-27416.r17">[17]</xref>&#x000a0;Some studies have suggested a cyclical pattern of&#x000a0;GCA and PMR in seasonal variation and incidence, implying possible environmental triggers.<xref ref-type="bibr" rid="article-27416.r18">[18]</xref>&#x000a0;Increased expression of toll-like receptors 7 and 9 in peripheral blood monocytes suggests the role of innate immunity in pathogenesis&#x000a0;as well.<xref ref-type="bibr" rid="article-27416.r19">[19]</xref></p>
      </sec>
      <sec id="article-27416.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PMR characteristically demonstrates symmetrical pain and stiffness in and around the shoulders, neck, and hip girdle. Pain and stiffness (lasting&#x000a0;longer than 45 minutes) are the worst in the morning and worsen after rest or prolonged inactivity. Restricted range of motion of the shoulders is common.&#x000a0;Patients often complain of pain and stiffness in the upper arms, hips, thighs, and upper and lower back. The onset of symptoms is rapid, usually from&#x000a0;a&#x000a0;day up to&#x000a0;2 weeks. It affects the quality of life as the pain may impair sleep at nighttime and daytime routine activities like getting out of bed or a chair, hooking a bra in the back, donning socks and shoes, taking a shower, hair brushing, driving, etc.<xref ref-type="bibr" rid="article-27416.r20">[20]</xref></p>
        <p>The pain and stiffness associated with PMR are most probably related to inflammation of the glenohumeral and hip joints and the subacromial, subdeltoid, and trochanteric bursae in the upper extremities.<xref ref-type="bibr" rid="article-27416.r21">[21]</xref>&#x000a0;Almost up to half of the patients experience systemic symptoms like fatigue, malaise, anorexia, weight loss, and/or low-grade fever.<xref ref-type="bibr" rid="article-27416.r22">[22]</xref> Persistent high fever is uncommon in PMR and should alert suspicion of GCA.<xref ref-type="bibr" rid="article-27416.r23">[23]</xref></p>
        <p>Peripheral involvement is also frequent with arthritis in a fourth&#x000a0;of patients. Other peripheral features like carpal tunnel syndrome, distal extremity swelling with pitting edema, and distal tenosynovitis can be present. Arthritis does not lead to erosions, deformities, or the development of rheumatoid arthritis.<xref ref-type="bibr" rid="article-27416.r24">[24]</xref>&#x000a0;Distal extremity swelling with pitting edema responds promptly to glucocorticoids.<xref ref-type="bibr" rid="article-27416.r25">[25]</xref>&#x000a0;An unusual distal manifestation is puffy edematous hand syndrome or remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome, comprised of explosive and abrupt clinical symptoms.</p>
        <p>On physical examination, diffuse tenderness is usually&#x000a0;present over the shoulder without localization to specific structures. The pain usually restricts the shoulder's active range of motion,&#x000a0;while the passive range of motion can be normal when carefully examined. Restriction of neck and hip movements because of pain is also common. Muscle tenderness of the neck, arms, and thighs may be present. Although the patient might complain of nonspecific weakness,&#x000a0;muscle strength is usually intact on a more thorough examination.<xref ref-type="bibr" rid="article-27416.r20">[20]</xref>&#x000a0;Tenderness to muscle palpation is a nonspecific sign and usually relates to articular or bursal involvement.</p>
      </sec>
      <sec id="article-27416.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>Elevated ESR is a common feature in PMR. The majority of authors consider ESR &#x0003e;40 mm/h significant.<xref ref-type="bibr" rid="article-27416.r26">[26]</xref><xref ref-type="bibr" rid="article-27416.r27">[27]</xref><xref ref-type="bibr" rid="article-27416.r28">[28]</xref>&#x000a0;ESR &#x0003c;40 mm/h is present in 5 to&#x000a0;20% of patients.<xref ref-type="bibr" rid="article-27416.r29">[29]</xref>&#x000a0;One study revealed ESR values &#x0003e;104 mm/h in 20% of patients.<xref ref-type="bibr" rid="article-27416.r29">[29]</xref> Patients with low ESR usually have a lower frequency of systemic features like fever, weight loss, and anemia. Response to therapy, the frequency of relapses, and the risk of developing GCA among these patients appear to be comparable with high ESR patients.<xref ref-type="bibr" rid="article-27416.r30">[30]</xref><xref ref-type="bibr" rid="article-27416.r31">[31]</xref> CRP is also typically&#x000a0;elevated. CRP was found to be a more sensitive&#x000a0;indicator of disease activity in&#x000a0;1 study, while ESR was found to be a superior predictor of relapse.<xref ref-type="bibr" rid="article-27416.r29">[29]</xref></p>
        <p>Normocytic anemia and thrombocytosis can occur. Liver enzymes, especially alkaline phosphatase, are occasionally elevated. Serologic tests, such as an antinuclear antibody (ANA), rheumatoid factor (RF), and anti-citrullinated protein antibodies (Anti-CCP AB), are negative. The creatine phosphokinase (CPK) value is within the normal range.</p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>
<bold>Ultrasound</bold>
</p>
        <p>Ultrasound is useful in diagnosing and monitoring treatment by assessing degrees of subacromial/subdeltoid bursitis, long-head biceps tenosynovitis, and glenohumeral synovitis. In&#x000a0;1 study, a power Doppler&#x000a0;(PD) signal at subacromial/subdeltoid&#x000a0;bursae&#x000a0;was&#x000a0;observed in a third of PMR patients. The positive PD signal at diagnosis correlated with&#x000a0;an increased&#x000a0;frequency of relapses, but the persistence&#x000a0;of PD findings did not correlate with relapses/recurrences.<xref ref-type="bibr" rid="article-27416.r32">[32]</xref> The 2012 ACR/EULAR PMR classification criteria include ultrasound.<xref ref-type="bibr" rid="article-27416.r33">[33]</xref></p>
        <p>
<bold>Magnetic Resonance Imaging&#x000a0;</bold>
</p>
        <p>Magnetic resonance imaging (MRI) helps depict bursitis, synovitis, and tenosynovitis in a similar way as&#x000a0;ultrasound does. However, it is more sensitive for hip and pelvic girdle findings.<xref ref-type="bibr" rid="article-27416.r34">[34]</xref> Pelvic MRI frequently shows bilateral,&#x000a0;peri-tendinous enhancement of pelvic girdle tendons and occasional low-grade hip synovitis. An enhancement of the proximal origin of rectus femoris appears to be a highly specific and sensitive finding.<xref ref-type="bibr" rid="article-27416.r35">[35]</xref></p>
        <p>
<bold>Positron Emission Tomography&#x000a0;</bold>
</p>
        <p>A<bold>&#x000a0;</bold>positron emission tomography (PET) scan shows 18&#x000a0;F-fluorodeoxyglucose (FDG) uptake in shoulders, ischial tuberosities, greater trochanters, and glenohumeral and sternoclavicular joints in patients with PMR.<xref ref-type="bibr" rid="article-27416.r36">[36]</xref>&#x000a0;The role of PET in diagnosing large vessel vasculitis is described&#x000a0;in a discussion below with GCA.&#x000a0;&#x000a0;</p>
        <p>
<bold>2012 Provisional Classification Criteria for Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative</bold>
</p>
        <p>Patients aged 50 years or older with bilateral shoulder aching and abnormal C-reactive protein concentrations or ESR, plus at least&#x000a0;4 points (without ultrasonography) or&#x000a0;5 points or more (with ultrasonography) from</p>
        <list list-type="bullet">
          <list-item>
            <p>Morning stiffness in excess of 45 minutes duration (2 points)</p>
          </list-item>
          <list-item>
            <p>Hip pain or restricted range of motion (1 point)</p>
          </list-item>
          <list-item>
            <p>Absence of rheumatoid factor or anti-citrullinated protein antibodies (2 points)</p>
          </list-item>
          <list-item>
            <p>Absence of other joint involvement (1 point)</p>
          </list-item>
          <list-item>
            <p>If ultrasonography is available, at least&#x000a0;1 shoulder with subdeltoid bursitis, biceps tenosynovitis or glenohumeral synovitis (either posterior or axillary), and at least&#x000a0;1 hip with synovitis or trochanteric bursitis (1 point)</p>
          </list-item>
          <list-item>
            <p>If ultrasonography is available, both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis (1 point)<xref ref-type="bibr" rid="article-27416.r33">[33]</xref></p>
          </list-item>
        </list>
        <p><italic toggle="yes">"A score=4 had 68% sensitivity and 78% specificity for discriminating all comparison subjects from PMR. The specificity was higher (88%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR. Adding ultrasound, a score=5 had increased sensitivity to 66% and specificity to 81%</italic>.<italic toggle="yes"> These criteria </italic>are not meant<italic toggle="yes"> for diagnostic&#x000a0;purposes."</italic><xref ref-type="bibr" rid="article-27416.r33">[33]</xref></p>
        <p>
<bold>Polymyalgia Rheumatica and Giant Cell Arteritis</bold>
</p>
        <p>PMR and GCA&#x000a0; frequently&#x000a0;overlap, and 20% of patients with PMR will get&#x000a0;diagnosed with GCA later. In biopsy-proven GCA, PMR features&#x000a0;are present in up to 50% of cases.<xref ref-type="bibr" rid="article-27416.r20">[20]</xref></p>
        <p>In a study, among patients with PMR with the persistence of classic symptoms but no cranial GCA-like symptoms, a PET/CT&#x000a0;scan&#x000a0;was positive for large vessel vasculitis in 60.7%. Inflammatory low back pain, pelvic girdle, and diffuse lower limb pain were also predictors of positive&#x000a0;PET/CT&#x000a0;scans in these patients.<xref ref-type="bibr" rid="article-27416.r37">[37]</xref> In another study, among patients who required higher doses of steroids or those who had atypical features like low-grade fever and weight loss, among others,&#x000a0;48% had large vessel vasculitis on PET/CT. Elevated CRP values were found to correlate with large vessel vasculitis.<xref ref-type="bibr" rid="article-27416.r38">[38]</xref></p>
        <p>In a study where a random sample of 68 patients with "pure" PMR, histological examinations of biopsy specimens of the temporal artery revealed inflammatory changes in only&#x000a0;3 patients (4.4%).<xref ref-type="bibr" rid="article-27416.r39">[39]</xref></p>
        <p>Patients with PMR should undergo evaluation for features suggestive of GCA at every&#x000a0;visit. A routine biopsy of&#x000a0;the temporal&#x000a0;artery&#x000a0;is not recommended.&#x000a0;Features like&#x000a0;the development of&#x000a0;a new&#x000a0;headache, vision and jaw&#x000a0;symptoms, tenderness and lack of pulses in the temporal&#x000a0;artery, lack of pulses in the periphery,&#x000a0;the persistence&#x000a0;of inflammatory&#x000a0;markers, high-grade fever, and refractoriness of classic&#x000a0;symptoms&#x000a0;are the red flags that should prompt&#x000a0;an urgent&#x000a0;evaluation for GCA&#x000a0;with imaging (chest/abdomen) such as CT angiography (CTA),&#x000a0;magnetic resonance angiography (MRA), or PET.</p>
      </sec>
      <sec id="article-27416.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Oral glucocorticoid (GC) therapy is a&#x000a0;well-proven&#x000a0;treatment.<xref ref-type="bibr" rid="article-27416.r40">[40]</xref><xref ref-type="bibr" rid="article-27416.r41">[41]</xref>&#x000a0;The essential points of&#x000a0;EULAR-ACR 2015 recommendations for management are summarized as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer 12.5 to 25&#x000a0;mg daily prednisone equivalent&#x000a0;as an initial therapy.</p>
          </list-item>
          <list-item>
            <p>Taper GCs gradually.</p>
          </list-item>
          <list-item>
            <p>Taper to an oral dose of 10 mg daily prednisone equivalent within 4 to 8 weeks.</p>
          </list-item>
          <list-item>
            <p>Once remission&#x000a0;is achieved, taper daily oral prednisone by 1 mg every&#x000a0;4 weeks&#x000a0;until discontinuation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treat for a minimum of 12 months.</p>
          </list-item>
          <list-item>
            <p>For relapse, increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4 to 8 weeks) to the dose at which the relapse occurred.</p>
          </list-item>
          <list-item>
            <p>Individualize&#x000a0;dose-tapering schedules based on regularly monitoring patient disease activity, laboratory markers, and adverse events.</p>
          </list-item>
          <list-item>
            <p>Administer lower doses of 7.5 to 10 mg daily for smaller patients with mild symptoms or brittle diabetes.</p>
          </list-item>
          <list-item>
            <p>Consider early introduction of methotrexate (MTX)&#x000a0;in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy, as well as in cases with risk factors, comorbidities, and/or concomitant medications where GC-related adverse events are more likely to occur.</p>
          </list-item>
        </list>
        <p>Clinical trials used MTX at oral doses of 7.5 to 10 mg/week.<xref ref-type="bibr" rid="article-27416.r40">[40]</xref>&#x000a0;A study shows&#x000a0;leflunomide&#x000a0;is an effective steroid-sparing agent that can also be used in PMR.<xref ref-type="bibr" rid="article-27416.r42">[42]</xref> It can be an alternative if the patient is not able to take MTX for various reasons.&#x000a0;Sparse data for&#x000a0;azathioprine exist for treating PMR, and&#x000a0;its use may be an option in cases with contraindications for methotrexate.<xref ref-type="bibr" rid="article-27416.r43">[43]</xref>&#x000a0;EULAR-ACR 2015 recommendations advise against the use of anti-TNF agents.<xref ref-type="bibr" rid="article-27416.r40">[40]</xref></p>
        <p>Most data for using tocilizumab (TCZ) in PMR&#x000a0;come from PMR coexisting with GCA. Case series and open-label studies have shown TCZ is useful in PMR with relapse or insufficient response to GC.<xref ref-type="bibr" rid="article-27416.r44">[44]</xref>&#x000a0;An open-label study suggested that relapse-free remission without GC treatment at&#x000a0;6 months was achievable in newly diagnosed patients with PMR.<xref ref-type="bibr" rid="article-27416.r45">[45]</xref> Randomized controlled trials&#x000a0;are needed&#x000a0;to evaluate if TCZ is routinely beneficial in certain patients with PMR.&#x000a0;</p>
        <p>Vitamin D and calcium supplementation are routine recommendations for patients on long-term steroids. Bisphosphonate prophylaxis is recommended for patients in moderate&#x000a0;to high fracture risk categories, including patients&#x000a0;older than 40 years with a fracture risk assessment (FRAX) score of &#x0003e;1% and &#x0003e;10% risk of hip and major osteoporotic fracture, respectively.<xref ref-type="bibr" rid="article-27416.r46">[46]</xref></p>
        <p>Close follow-up is recommended.&#x000a0;Guidelines published by BSR and BHPR&#x000a0;recommend follow-up at weeks 0, 1 to 3, and 6, then months 3, 6, 9, and 12 in the first year (with extra visits for relapses or adverse events).<xref ref-type="bibr" rid="article-27416.r47">[47]</xref>&#x000a0;It seems prudent to follow up with patients every&#x000a0;3 months until remission and, after that, every&#x000a0;6 months to&#x000a0;1 year to monitor for recurrence. CRP and ESR help monitor disease activity, and some data indicate CRP as a more sensitive marker.<xref ref-type="bibr" rid="article-27416.r29">[29]</xref></p>
        <p>Relapses often entail increased ESR and CRP and the return of symptoms. Increased risk of relapse is found to correlate with a higher initial dose of steroid used, rapid steroid tapering, HLA-DRB1*0401, and persistently high inflammatory markers.<xref ref-type="bibr" rid="article-27416.r13">[13]</xref><xref ref-type="bibr" rid="article-27416.r48">[48]</xref><xref ref-type="bibr" rid="article-27416.r49">[49]</xref></p>
        <p>Managing relapses can be challenging. The usual approach is as follows:</p>
        <list list-type="order">
          <list-item>
            <p>For patients with recurrent symptoms developing following discontinuation of GCs and accompanied by an elevation in the CRP and/or ESR, GCs can be restarted at the original dose that managed symptoms.</p>
          </list-item>
          <list-item>
            <p>For patients who relapse several times, it is reasonable to lengthen the&#x000a0;interval between dose reductions to&#x000a0;6 to&#x000a0;8 weeks.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27416.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>PMR has nonspecific features that many other entities can mimic. Other entities should be excluded from investigations before diagnosing PMR, as deemed necessary by clinical suspicion.<xref ref-type="bibr" rid="article-27416.r22">[22]</xref><xref ref-type="bibr" rid="article-27416.r50">[50]</xref>&#x000a0;Differential diagnoses are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Crown dens syndrome&#x000a0;<xref ref-type="bibr" rid="article-27416.r51">[51]</xref></p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Obstructive sleep apnea</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Viral infections&#x000a0;such as EBV, hepatitis, human immunodeficiency virus, parvovirus B19</p>
          </list-item>
          <list-item>
            <p>Systemic bacterial infections, septic arthritis</p>
          </list-item>
          <list-item>
            <p>Cancer</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome&#x000a0;<xref ref-type="bibr" rid="article-27416.r52">[52]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27416.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PMR has an excellent prognosis when the&#x000a0;diagnosis is made promptly, and appropriate treatment is initiated. Mortality among individuals with&#x000a0;PMR is not significantly increased compared to the general population.<xref ref-type="bibr" rid="article-27416.r53">[53]</xref></p>
      </sec>
      <sec id="article-27416.s11" sec-type="Complications">
        <title>Complications</title>
        <p>According to different studies,&#x000a0;PMR patients have an increased risk of cardiovascular diseases by 1.15 to 2.70. Premature atherosclerosis resulting from chronic inflammation is the most likely cause of premature CAD.<xref ref-type="bibr" rid="article-27416.r54">[54]</xref></p>
        <p>A cancer association with PMR is not entirely clear.<xref ref-type="bibr" rid="article-27416.r55">[55]</xref> In a study of the increased risk of lymphoplasmacytic lymphoma, Waldenstrom&#x000a0;macroglobulinemia correlated with PMR with an odds ratio (OR) of 2.9.<xref ref-type="bibr" rid="article-27416.r56">[56]</xref></p>
        <p>PMR patients have a higher chance of developing inflammatory arthritis. Features of small joint synovitis, younger age, and positive anti-CCP positivity&#x000a0;in patients with PMR were associated with the risk of developing inflammatory arthritis.<xref ref-type="bibr" rid="article-27416.r57">[57]</xref></p>
      </sec>
      <sec id="article-27416.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Referral to a rheumatologist is suggested if there are atypical features (eg, presenting fever, younger patients),&#x000a0;an inadequate response to initial&#x000a0;GC treatment, prominent peripheral arthritis, or difficulties with&#x000a0;GC tapering.</p>
      </sec>
      <sec id="article-27416.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and prevention strategies for PMR primarily revolve around early recognition, accurate diagnosis, and timely initiation of appropriate treatment. Since PMR predominantly affects individuals older than 50 years, proactive screening and awareness campaigns among this age group may facilitate early identification of symptoms, enabling prompt medical intervention. Additionally, raising awareness among healthcare professionals about the clinical features and diagnostic criteria for PMR can improve detection rates.</p>
        <p>Implementing routine monitoring of inflammatory markers, such as ESR and CRP, in older populations with musculoskeletal complaints can aid in early detection. Moreover, educating the public on lifestyle factors that may impact inflammatory conditions and promoting regular physical activity and a healthy diet may play a role in preventing or mitigating the severity of PMR.</p>
        <p>Patients should be thoroughly counseled regarding the risks and benefits of&#x000a0;GC treatment. Patients should also be encouraged to adhere to their medication regimens and long-term follow-up to minimize the risk of disease recurrence and potential side effects of medications. Patients should also be made aware of the importance of taking calcium and vitamin D supplements.</p>
        <p>Overall, a multifaceted approach that combines public awareness, healthcare provider education, and proactive screening holds promise for enhancing deterrence and prevention efforts against the impact of PMR.</p>
      </sec>
      <sec id="article-27416.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind regarding polymyalgia rheumatica&#x000a0;are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic patients with elevations in the ESR and/or CRP do not require increased doses of GCs.</p>
          </list-item>
          <list-item>
            <p>Fibromyalgia-like symptoms,&#x000a0;such as widespread muscle pain associated with fatigue and stiffness, have been reported during the tapering phase of longstanding&#x000a0;GC therapy in PMR patients and can be managed by chronic low doses of GCs.</p>
          </list-item>
          <list-item>
            <p>Physical therapy can benefit an&#x000a0;older adult who has become deconditioned but has no role in initial management.</p>
          </list-item>
          <list-item>
            <p>Nonsteroidal anti-inflammatory drugs (NSAIDs) have no therapeutic role in the initial management of PMR.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27416.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of PMR is best&#x000a0;accomplished using an interprofessional team approach. Patients with PMR usually receive an initial evaluation&#x000a0;by primary care clinicians. A low threshold for suspicion, timely referral to rheumatology, and excluding giant cell arteritis are essential aspects in the initial care of these patients. PMR has a long list of differentials and mimickers, and diagnosis&#x000a0;may be even more challenging if the patient already&#x000a0;has&#x000a0;1 of those as a coexisting condition.</p>
        <p>Once&#x000a0;PMR is diagnosed, the pharmacist should be consulted regarding dosing and potential interactions with the patient's drug regimen. The pharmacist can also counsel patients regarding their medications and warn them of possible adverse effects. If the pharmacist notes any concerns, he should inform the prescriber immediately for therapeutic changes.</p>
        <p>Nursing likewise plays a crucial role in these cases, as they will have more patient contact, can counsel the patient about their condition, and must report any concerns or changes in the patient's condition to the clinicians immediately, noting the changes and reasons for concern, so the clinicians can follow-up and make any therapeutic changes necessary.&#x000a0;</p>
        <p>Essential aspects of long-term management include frequent follow-up, vigilance&#x000a0;in detecting developing GCA, and managing relapse or refractory disease. Strong coordination and peer-to-peer communication within the interprofessional team are essential for good outcomes and an optimal care model.</p>
      </sec>
      <sec id="article-27416.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27416&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27416">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/polymyalgia-rheumatica/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27416">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27416/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27416">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27416.s17">
        <title>References</title>
        <ref id="article-27416.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liozon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ouattara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rhaiem</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bezanahary</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loustaud</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Letellier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Drouet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2009</year>
            <season>Jan-Feb</season>
            <volume>27</volume>
            <issue>1 Suppl 52</issue>
            <fpage>S89</fpage>
            <page-range>S89-94</page-range>
            <pub-id pub-id-type="pmid">19646354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Hicok</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Goronzy</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>514</fpage>
            <page-range>514-20</page-range>
            <pub-id pub-id-type="pmid">8147928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Gay</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica.</article-title>
            <source>Arthritis Res</source>
            <year>2001</year>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>154</fpage>
            <page-range>154-7</page-range>
            <pub-id pub-id-type="pmid">11299056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Elling</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection.</article-title>
            <source>J Rheumatol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-9</page-range>
            <pub-id pub-id-type="pmid">8838518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uddhammar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juto</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rantap&#x000e4;&#x000e4; Dahlqvist</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>1997</year>
            <season>May-Jun</season>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-302</page-range>
            <pub-id pub-id-type="pmid">9177926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemauer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Modrow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Georgi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Helmke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vaith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;lmerich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Straub</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>There is no association between polymyalgia rheumatica and acute parvovirus B19 infection.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>657</fpage>
            <pub-id pub-id-type="pmid">10577374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narv&#x000e1;ez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clavaguera</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Nolla-Sol&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Valverde-Garcia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roig-Escofet</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Lack of association between infection and onset of polymyalgia rheumatica.</article-title>
            <source>J Rheumatol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>953</fpage>
            <page-range>953-7</page-range>
            <pub-id pub-id-type="pmid">10782822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scrivo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gerardi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rutigliano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mipatrini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stricchiola</surname>
                <given-names>GMG</given-names>
              </name>
              <name>
                <surname>Pacella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Altobelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castellani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alessandri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ceccarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Franco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riccieri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sili Scavalli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>La Torre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valesini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study.</article-title>
            <source>Clin Rheumatol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>2573</fpage>
            <page-range>2573-2577</page-range>
            <pub-id pub-id-type="pmid">29732494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verrecchia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marinaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giovinale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fonnesu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Landolfi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manna</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature.</article-title>
            <source>Lupus</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-7</page-range>
            <pub-id pub-id-type="pmid">22235046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raheel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shbeeb</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1282</fpage>
            <page-range>1282-1285</page-range>
            <pub-id pub-id-type="pmid">27768840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partington</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Helliwell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Abdul Sultan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1750</fpage>
            <page-range>1750-1756</page-range>
            <pub-id pub-id-type="pmid">30297332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern.</article-title>
            <source>Ann Intern Med</source>
            <year>1995</year>
            <month>Aug</month>
            <day>01</day>
            <volume>123</volume>
            <issue>3</issue>
            <fpage>192</fpage>
            <page-range>192-4</page-range>
            <pub-id pub-id-type="pmid">7598301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cantini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Macchioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Consonni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bajocchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vinceti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catanoso</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pulsatelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meliconi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boiardi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2005</year>
            <month>Feb</month>
            <day>15</day>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-8</page-range>
            <pub-id pub-id-type="pmid">15696567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hicok</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Goronzy</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.</article-title>
            <source>Ann Intern Med</source>
            <year>1994</year>
            <month>Oct</month>
            <day>01</day>
            <volume>121</volume>
            <issue>7</issue>
            <fpage>484</fpage>
            <page-range>484-91</page-range>
            <pub-id pub-id-type="pmid">8067646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burkel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Moosig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
            </person-group>
            <article-title>Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>35 Suppl 103</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-97</page-range>
            <pub-id pub-id-type="pmid">27974093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Geest</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Abdulahad</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chalan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horst</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Huitema</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Roffel</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Roozendaal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kluin</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Boots</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>1927</fpage>
            <page-range>1927-38</page-range>
            <pub-id pub-id-type="pmid">24623536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Audia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fraszczak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ornetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lakomy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ciudad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leguy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berthier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vinit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manckoundia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maillefert</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Besancenot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Aho-Glele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>Lorcerie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Janikashvili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Larmonier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bonnotte</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>3788</fpage>
            <page-range>3788-98</page-range>
            <pub-id pub-id-type="pmid">22833233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Gay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vazquez-Rodriguez</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Lopez-Diaz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miranda-Filloy</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gonzalez-Juanatey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Llorca</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of giant cell arteritis and polymyalgia rheumatica.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>Oct</month>
            <day>15</day>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>1454</fpage>
            <page-range>1454-61</page-range>
            <pub-id pub-id-type="pmid">19790127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guggino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrante</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Macaluso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Triolo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ciccia</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of polymyalgia rheumatica.</article-title>
            <source>Reumatismo</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-17</page-range>
            <pub-id pub-id-type="pmid">29589398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Gay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Oct</month>
            <day>07</day>
            <volume>390</volume>
            <issue>10103</issue>
            <fpage>1700</fpage>
            <page-range>1700-1712</page-range>
            <pub-id pub-id-type="pmid">28774422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Breuer</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update.</article-title>
            <source>Rambam Maimonides Med J</source>
            <year>2016</year>
            <month>Oct</month>
            <day>31</day>
            <volume>7</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">27824543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Dejaco</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia Rheumatica.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>May</month>
            <day>02</day>
            <volume>166</volume>
            <issue>9</issue>
            <fpage>ITC65</fpage>
            <page-range>ITC65-ITC80</page-range>
            <pub-id pub-id-type="pmid">28460395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greigert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ornetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maillefert</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bonnotte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Dec</month>
            <day>14</day>
            <volume>11</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">36556036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cantini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Macchioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Padula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boiardi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study.</article-title>
            <source>Arthritis Rheum</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1221</fpage>
            <page-range>1221-6</page-range>
            <pub-id pub-id-type="pmid">9663479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases.</article-title>
            <source>Arthritis Rheum</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">8546741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chuang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Ilstrup</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>LT</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.</article-title>
            <source>Ann Intern Med</source>
            <year>1982</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>672</fpage>
            <page-range>672-80</page-range>
            <pub-id pub-id-type="pmid">6982645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Healey</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of polymyalgia rheumatica: evidence for synovitis.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1984</year>
            <month>May</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>322</fpage>
            <page-range>322-8</page-range>
            <pub-id pub-id-type="pmid">6729485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bird</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Esselinckx</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mowat</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of criteria for polymyalgia rheumatica.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1979</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>434</fpage>
            <page-range>434-9</page-range>
            <pub-id pub-id-type="pmid">518143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Macchioni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ranzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Padula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boiardi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">10966209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Gay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Valverde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Sueiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Armona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Taboada</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome.</article-title>
            <source>Arch Intern Med</source>
            <year>1997</year>
            <month>Feb</month>
            <day>10</day>
            <volume>157</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-20</page-range>
            <pub-id pub-id-type="pmid">9040299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.</article-title>
            <source>J Rheumatol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1333</fpage>
            <page-range>1333-7</page-range>
            <pub-id pub-id-type="pmid">10381052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macchioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Catanoso</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pipitone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boiardi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>1566</fpage>
            <page-range>1566-9</page-range>
            <pub-id pub-id-type="pmid">19808693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dasgupta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cimmino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bachta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dejaco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duftner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Duhaut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Po&#x000f3;r</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaposi</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Mandl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Balint</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Iagnocco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cantini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Macchioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pipitone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Del Amo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esp&#x000ed;gol-Frigol&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Taboada</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Nordborg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Direskeneli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hazleman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pease</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abril</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michet</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonter</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Maz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>943</fpage>
            <page-range>943-54</page-range>
            <pub-id pub-id-type="pmid">22389040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huwart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garrigues</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jousse-Joulin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marhadour</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guellec</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cornec</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gouillou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saraux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devauchelle-Pensec</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2018</year>
            <month>Jan</month>
            <day>25</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">29370856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fruth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buehring</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>36 Suppl 114</volume>
            <issue>5</issue>
            <fpage>86</fpage>
            <page-range>86-95</page-range>
            <pub-id pub-id-type="pmid">30296970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing polymyalgia rheumatica on <sup>18</sup>F-FDG PET/CT: typical uptake patterns.</article-title>
            <source>Ann Nucl Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>573</fpage>
            <page-range>573-577</page-range>
            <pub-id pub-id-type="pmid">29948622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto-Pe&#x000f1;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Rodr&#x000ed;guez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Loricera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banzo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n-Goercke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calvo-R&#x000ed;o</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Vela</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corrales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Gay</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
            </person-group>
            <article-title>Predictors of positive <sup>18</sup>F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>720</fpage>
            <page-range>720-727</page-range>
            <pub-id pub-id-type="pmid">29903537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ar&#x000e9;valo Ruales</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negueroles Albuixech</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loaiza Gongora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grau Garc&#x000ed;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ivorra Cort&#x000e9;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n Ivorra</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>18 F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with polymyalgia rheumatica: Screening for vasculitis.</article-title>
            <source>Reumatol Clin (Engl Ed)</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-41</page-range>
            <pub-id pub-id-type="pmid">29550251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myklebust</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gran</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.</article-title>
            <source>Br J Rheumatol</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1161</fpage>
            <page-range>1161-8</page-range>
            <pub-id pub-id-type="pmid">8948307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dejaco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Perel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Camellino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abril</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bachta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balint</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barraclough</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bianconi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buttgereit</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carsons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ching</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cimmino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diamantopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Docken</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Duftner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fashanu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hildreth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hollywood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maharaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martinez-Taboada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neill</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nordborg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Padbury</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pease</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tronnier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whitlock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>B</given-names>
              </name>
              <collab>European League Against Rheumatism</collab>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1799</fpage>
            <page-range>1799-807</page-range>
            <pub-id pub-id-type="pmid">26359488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donskov</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hauge</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Toro-Guti&#x000e9;rrez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Hemmig</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Van der Maas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gheita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>KMJ</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rezus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Sattui</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Matza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ocampo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gromova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Appenzeller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goecke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keen</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harifi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erraoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ziade</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Al-Ani</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ajibade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knitza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fr&#x000f8;lund</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pimentel-Quiroz</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Lyrio</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sandovici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van der Geest</surname>
                <given-names>KSM</given-names>
              </name>
              <name>
                <surname>Helliwell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dejaco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2023</year>
            <month>Aug</month>
            <day>01</day>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>2797</fpage>
            <page-range>2797-2805</page-range>
            <pub-id pub-id-type="pmid">36637182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diamantopoulos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Hetland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Myklebust</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>120638</fpage>
            <pub-id pub-id-type="pmid">24106691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Silva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hazleman</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-8</page-range>
            <pub-id pub-id-type="pmid">3511861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toussirot</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>R&#x000e9;gent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devauchelle-Pensec</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saraux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?</article-title>
            <source>RMD Open</source>
            <year>2016</year>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>e000305</fpage>
            <pub-id pub-id-type="pmid">27738520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lally</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Forbess</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hatzis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>10</issue>
            <fpage>2550</fpage>
            <page-range>2550-4</page-range>
            <pub-id pub-id-type="pmid">27159185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Magrey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Byun Robinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wolver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1095</fpage>
            <page-range>1095-1110</page-range>
            <pub-id pub-id-type="pmid">28585410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dasgupta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borg</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barraclough</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bourke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fulcher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hollywood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Power</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samanta</surname>
                <given-names>A</given-names>
              </name>
              <collab>BSR and BHPR Standards, Guidelines and Audit Working Group</collab>
            </person-group>
            <article-title>BSR and BHPR guidelines for the management of polymyalgia rheumatica.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>186</fpage>
            <page-range>186-90</page-range>
            <pub-id pub-id-type="pmid">19910443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Gay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Porr&#x000fa;a</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Caruncho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dababneh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hajeer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ollier</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.</article-title>
            <source>J Rheumatol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1326</fpage>
            <page-range>1326-32</page-range>
            <pub-id pub-id-type="pmid">10381051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kremers</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Reinalda</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Zinsmeister</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Relapse in a population based cohort of patients with polymyalgia rheumatica.</article-title>
            <source>J Rheumatol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-73</page-range>
            <pub-id pub-id-type="pmid">15630727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumanomido</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kusunoki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Crowned Dens Syndrome: Report of Three Cases and a Review of the Literature.</article-title>
            <source>J Emerg Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>e9</fpage>
            <page-range>e9-e13</page-range>
            <pub-id pub-id-type="pmid">25910825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ichibayashi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Physical findings of crowned dens syndrome.</article-title>
            <source>Clin Case Rep</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>e6852</fpage>
            <pub-id pub-id-type="pmid">36698514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Brouner</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grigorian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Baumrucker</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Syndrome of Remitting Seronegative Symmetrical Synovitis with Pitting Edema-A Rare but Treatable Condition in Palliative Medicine.</article-title>
            <source>Palliat Med Rep</source>
            <year>2022</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>322</fpage>
            <page-range>322-325</page-range>
            <pub-id pub-id-type="pmid">36636613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doran</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.</article-title>
            <source>J Rheumatol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>1694</fpage>
            <page-range>1694-7</page-range>
            <pub-id pub-id-type="pmid">12180732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koster</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Warrington</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies.</article-title>
            <source>Rheumatol Int</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-149</page-range>
            <pub-id pub-id-type="pmid">27577940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatzigeorgiou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Comorbidity in polymyalgia rheumatica.</article-title>
            <source>Reumatismo</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-43</page-range>
            <pub-id pub-id-type="pmid">29589401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristinsson</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Koshiol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rkholm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>McMaster</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Turesson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2010</year>
            <month>Apr</month>
            <day>21</day>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>557</fpage>
            <page-range>557-67</page-range>
            <pub-id pub-id-type="pmid">20181958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27416.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yates</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Luben</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2019</year>
            <month>May</month>
            <volume>78</volume>
            <issue>5</issue>
            <fpage>704</fpage>
            <page-range>704-705</page-range>
            <pub-id pub-id-type="pmid">30366946</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
